nancy, france - avm 2018 · serge bracard georges rodesch chair co-chair organizing committee serge...
TRANSCRIPT
WelcomeBrain arterio venous malformations are highly complex vascular
lesions that may have devastating consequences, and that
require often multidisciplinary approaches and decisions.
Knowledges on physiopathology, biology, or natural history
of these diseases are still in progress or controversial, even if
considerable advancements have been achieved over the past
decade, allowing improved managements of the patients.
The aim of the 2nd World AVM meeting is to focus on the latest
information available about arteriovenous malformations of the
brain. It will gather recognized experts in their field in order
to allow them to share their experiences and to discuss the
potential benefits that can be currently brought to our patients.
The 1st World AVM Congress held in Edinburgh in 2012 was
a true success and the participants expressed their interest in
such a multidisciplinary meeting devoted to this complex lesion.
Warm welcome in Nancy today to continue the discussion that
began in 2012 and we look forward for more advanced debates.
Serge Bracard Georges RodeschChair Co-Chair
Organizing CommitteeSerge Bracard (Chair)Georges Rodesch (Co-Chair)Luc Picard (Honorary President)
Scientific CommitteeAl-Shahi Salman Rustam Christophe Cognard Douglas KondziolkaMichael Lawton Christer Lindquist Jay P. MohrFrançois Proust Robin Sellar Michael Söderman Christian Stapf Gary Steinberg Peter VajkoczyWilliam L Young †
Local Organizing CommitteeRené AnxionnatValérie BernierMarc BraunXavier Ducrocq Francis Guillemin Olivier Klein
Nancy, France 18-20 june 2014
Programme
3
Wednesday 18th of June 2014
14:00-14:10 OPENING CEREMONY
14:10-16:15 SESSION 1: Fundamental sciences: origin, pathophysiology, experimental AVMs, angiogenesis Chairmen: F. LING, Beijing, CHINA G. RODESCH, Suresnes, FRANCE
14:10-14:40 Origin and growth of AVMs: biological factors and angiogenesis M.T. LAWTON, San Francisco, UNITED STATES
14:40-15:00 Endothelial Notch signalling in AVMs R. WANG, San Francisco, UNITED STATES
15:00-15:20 HHT and brain AVMs K. TER BRUGGE, Toronto, CANADA
15:20-15:40 AVMs: RASA 1 and other genetical diseases M. VIKKULA, Brussels, BELGIUM
15:40-16:00 AVMs: genetical and biological factors of rupture K. KLIJN, Utrecht, NETHERLANDS
16:00-16:15 DISCUSSION
16:15-16:45 COFFEE BREAK
16:45-18:30 SESSION 2: Epidemiology, natural history, consequences on the brain Chairmen: E. HOUDART, Paris, FRANCE P. VILELA Lisboa, PORTUGAL
16:45-17:10 Cerebral veins: from anomalies to brain AVM’s G. RODESCH, Suresnes, FRANCE
17:10-17:30 Epidemiology, natural history and clinical factors for rupture of BAVMs H. KIM, San Francisco, UNITED STATES
17:30-17:50 AVMs and maturating brain: pathophysiology J.J. BHATTACHARYA, Glasgow, UNITED KINGDOM
17:50-18:10 Functional cerebral consequences of BAVMs: the interest of MRI S. KOLLIAS, Zurich, SWITZERLAND
18:10-18:30 DISCUSSION
Programme
4
Thursday 19th of June 2014
08:30-10:15 SESSION 3: Angioarchitecture and AVM influence on the surrounding brain Chairmen: M. LEONARDI, Bologna, ITALY M.T LAWTON, San Francisco, UNITED STATES
08:30-09:00 Brain AVM and histogenetic units: from biology to interest in the therapeutic management A. VALAVANIS, Zurich, SWITZERLAND
09:00-09:20 Clinical expression and therapeutic complications: arteries and nidus K. TER BRUGGE, Toronto, CANADA
09:20-09:40 Clinical expression and therapeutic complications: veins S. BRACARD, Nancy, FRANCE
09:40-10:00 Perinidal vessels S. SATO, Fukushima, JAPAN
10:00-10:15 DISCUSSION
10:15-10:45 COFFEE BREAK
10:45-12:30 SESSION 4: Should AVMs be treated? Chairmen: M. MUTO, Naples, ITALY ; K. TER BRUGGE, Toronto, CANADA
10:45-11:05 Ruptured AVMs P. VAJKOCZY, Berlin, GERMANY
11:05-11:20 DISCUSSION
11:20-11:40 Non ruptured AVMs: what the literature tells us J.P. MOHR, New York, UNITED STATES
11:40-12:05 ARUBA study: and now? C. STAPF, Paris, FRANCE
12:05-12:30 DISCUSSION
12:30-13:30 LUNCH BREAK
12:30-13:15 INDUSTRY SPONSORED SYMPOSIUM LEVEL 2, ROOM JEAN LAMOUR-HÉRÉ
Nancy, France 18-20 june 2014
Programme
5
13:30-15:10 SESSION 5: Treatments: state of the art and future perspectives (1) Chairmen: J.P. MOHR, New York, UNITED STATES C. MOUNAYER, Limoges, FRANCE
13:30-13:50 Surgical treatment M.T. LAWTON, San Francisco, UNITED STATES
13:50-14:10 Combined treatments: embolization and surgery G. STEINBERG, Stanford, UNITED STATES
14:10-14:30 Endovascular treatments: arterial approaches with glue and Onyx. Indications. Results S. MANGIAFICO, Firenze, ITALY
14:30-14:50 Endovascular treatments: venous and combined approaches. Indications. Results J. MORET, Clichy, FRANCE
14:50-15:10 Histopathology of AVMs after endovascular treatments L. SEKHAR, Seatle, UNITED STATES
15:10-15:40 COFFEE BREAK
15:40-18:30 SESSION 6: Treatments: state of the art and future perspectives (2) Chairmen: V. BERNIER, Nancy, FRANCE R. SELLAR, Edinburgh, UNITED KINGDOM
15:40-16:00 Radiosurgery: Gamma Knife C.P YEN, Charlottesville, UNITED STATES
16:00-16:20 Radiosurgery: Cyberknife U. FORNEZZA, Vicenza, ITALY
16:20-16:35 Delineation of the AVM target for proper radiosurgery R. ANXIONNAT, Nancy, FRANCE
16:35-16:50 Radiosurgery after embolization with glue D. KONDZIOLKA, New York, UNITED STATES
16:50-17:10 Radiosurgery after embolization with Onyx A. KANNER, Tel Aviv, ISRAEL
17:10-17:30 Late complications of radiosurgery: pathophysiology and management C. LINDQUIST, London, UNITED KINGDOM
17:30-18:30 ROUND TABLE AND CASES DISCUSSIONS: Evaluation of therapeutic risks: can specific disease groups and risk scales be determined? U. FORNEZZA, D. KONDZIOLKA, E. HOUDART, J.P LEJEUNE, J.P MOHR, J. MORET, C. STAPF, A. VALAVANIS, M. ZERAH
18:30-19:15 INDUSTRY SPONSORED SYMPOSIUM LEVEL 2, ROOM JEAN LAMOUR-HÉRÉ
Programme
6
Friday 20th of June 201408:30-10:15 SESSION 7: Specific problems, incomplete, palliative, targetted
treatments Chairmen: E. PELINCA DA COSTA, Natal, BRAZIL C. STAPF, Paris, FRANCE
08:30-08:50 Proliferative angiopathy and other false brain AVMs G. RODESCH, Suresnes, FRANCE
08:50-09:10 Partial targetted radiosurgery C.P. YEN, Charlottesville, UNITED STATES
09:10-09:30 Histopathology of AVMs after radiosurgery G. SZEIFERT, Budapest, HUNGARY
09:30-09:50 Recurrent radiosurgical treatments D. KONDZIOLKA, New York, UNITED STATES
09:50-10:15 Anti angiogenic treatments: where do we stand? H. KIM, San Francisco, UNITED STATES
10:15-10:45 COFFEE BREAK
10:45-12:45 SESSION 8: How to evaluate the therapeutic results? Chairmen: O. KLEIN, Nancy, FRANCE D. ROY, Montreal, CANADA
10:45-11:05 Should cured AVMs be controlled? J.P LEJEUNE, Lille, FRANCE
11:05-11:25 Are pediatric AVMs curable? M. ZERAH, Paris, FRANCE
11:25-11:45 How to assess the cure of a brain AVM? M. SÖDERMAN, Stockholm, SWEDEN
11:45-12:05 Is a post therapeutic reliquat of a brain AVM acceptable? F. PROUST, Rouen, FRANCE
12:05-12:25 Radioanatomical versus clinical cure of brain AVMs L. PICARD, Nancy, FRANCE
12:25-12:45 What have we learned from our colleagues? Need for a new classification or a new study? G. STEINBERG, Stanford, UNITED STATES G. RODESCH, Suresnes, FRANCE
S. BRACARD, Nancy, FRANCE
12:45-13:00 CLOSING CEREMONY
Nancy, France 18-20 june 2014
7
General information
Congress venueCongress Centre of Nancy 17-19 Rue Grand Rabbin Haguenauer - 54000 Nancy France
Plenary Sessions Level 0, Amphitheatre Stanislas
Preview RoomLevel -1, Salle Vaudémont
Coffee break and lunch buffet Level 3, served on the exhibition area
E-poster corner Level 3, exhibition area
Exhibition area Level 3
Accreditation The 2nd World AVM Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 12 European CME credits (ECMEC). Your certificate will be available on the website from the 24th of June 2014.
Certificate of attendance Your certificate of attendance for the 2nd World AVM Congress will be available on the website from the 24th of June 2014.
Social programmeWelcome cocktail, June 18th at 19:30, Musée des Beaux Art, 1 rue Gustave Simon (10 min walking distance)
Useful information Train: The SNCF website: www.sncf.frPlane: Metz-Nancy Lorraine Airport Tel.: +33(0) 387 567 000Paris Charles de Gaulle Airport Tel.: +33 (0) 170 363 950 https://www.aeroportsdeparis.fr
Nancy best tourist sites • Place Stanislas • Arc de Triomphe • Musée des Beaux-Arts • Musée historique lorrain • Église des Cordeliers • Hôtel de ville de Nancy
For further tourist attractions, please visit: http://www.planetware.com/tourist-attractions-/nancy-f-lor-nan.htm
Tourist information Nancy TourismePlace Stanislas 54011 Nancy Cedex Tel: +33 (0) 383 352 241www.nancy-tourisme.fr/nancy-tourism/home
Registration and information
19, allées Jean Jaurès - BP 6150831015 Toulouse - FRANCETèl: +33 (0)5 34 45 26 45Email: [email protected]
• Palais Ducal • Cathédrale Notre-Dame • Église Notre-Dame-de-Bon-Secours • Église Saint-Sébastien • Jardin botanique et conservatoire du
Montet
• Musée-Aquarium de Nancy • Place de la Carrière • Basilique Saint-Epvre • Musée des Arts et Traditions
populaires • Parc de la Pépinière
8
Industrial symposium
Exhibition map
Nancy, France 18-20 june 2014
Thursday, 19th of June12:30 - 13:15 ORGANIZED BY COVIDIEN LEVEL 2, ROOM JEAN LAMOUR-HÉRÉ Lunch bag buffet
Topic AVM treatment in 2014: Knows, Unknowns and impact of the ARUBA trial.
Speakers 10 years of experience with Onyx™ liquid embolic system & ARUBA study, what is the current role of INRs in the treatment of AVMs
S. Mangiafico, Firenze, ITALY
Day to day on the ground experience of Onyx™ liquid embolic system in a Spanish center and how ARUBA changed my Role in AVMs treatment
S. Pedro, Madrid, SPAIN
Experience with Onyx™ liquid embolic system, my current practice and impact of ARUBA trial on it H. Nordmeyer, Essen, GERMANY
18:30 - 19:15 ORGANIZED BY BRAINLAB LEVEL 2, ROOM JEAN LAMOUR-HÉRÉ Wine and cheese buffet
Topic Disseminating best practice through automated software with Brainlab Elements
Speakers The potential of hypo-fractionated radiosurgery A. A.F. De Salles, Los Angeles, UNITED STATES OF AMERICA
Maximizing the impact of embolization Y. Murayama, Tokyo, JAPAN
Color intensity projection of cerebral digital subtraction angiography F. Lagerwaard, Amsterdam, THE NETHERLANDS
Decoding the brain´s pulse for quickly identifying vascular anomalies P. Lovoi, Mountain View California, UNITED STATES OF AMERICA
Comprehensive nidus definition with Smart Brush Angio A. Malesevic, Munich, GERMANY
9
PLATINUM LEVEL
GOLD LEVEL
SILVER LEVEL
THANKS ALSO TO:GEM SRL / Queryo Medical
Stryker NeurovascularGE Healthcare
Penumbra
Thanks to our sponsors
10
Companies
Nancy, France 18-20 june 2014
BALT EXTRUSION BOOTH NUMBER 03Presentation BALT is a family company who has grown with and followed the evolution of interventional radiology since its creation in 1977, and who distributes its products in more than 90 countries in the world.BALT constantly focuses on the development of technologies and materials applied to medical devices (micro mechanics, metallurgy and chemistry). This strategy has enabled BALT to stay on the leading edge of innovation for many years, maintaining its financial as well as its technical independence.
Website http://www.balt.fr
Address 10, rue Croix Vigneron 95160 MONTMORENCY - France
Email [email protected]
BRAINLAB BOOTH NUMBER 02Presentation Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to and consistency of advanced, less invasive patient treatment.Brainlab technology currently powers treatments in the fields of neurosurgery, orthopedics, ENT, CMF, spine, trauma and radiation therapy. Privately held since its formation in 1989, Brainlab has more than 5,000 systems installed in about 95 countries.
Website http://www.brainlab.com
Address Kapellenstrasse 12 - 85622 FELDKIRCHEN - Germany
Email [email protected]
COVIDIEN BOOTH NUMBER 01Presentation Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries.
Website http://www.covidien.com
Address 20 Lower Hatch Street - DUBLIN 2 - Ireland
Email http://www.covidien.com/contact
11
Companies
ELEKTA BOOTH NUMBER 05 PresentationElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both heal.
Website http://www.elekta.com
Address Box 7593 - 10393 STOCKHOLM - Sweden
Contact LOTTA SÄRNMAN
Email [email protected]
Phone +46 708117463
GE HEALTHCARE BOOTH NUMBER 04Presentation GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
Website http://www3.gehealthcare.com/en/Products/Categories/Interventional_Image_Guided_Systems/IGS_for_Interventional_Neuroradiology/Innova_IGS_630
Address 283 Rue de la Minière - 78533 Buc - France
Contact PHILIPPE KARAM
Email [email protected]
Phone +33 800 90 87 19
13
Companies
GEM SRL / QUERYO MEDICAL SAS BOOTH NUMBER 06 PresentationGEM srl produces and distributes Glubran2 surgical glue all over the world. Glubran2 is used for endovascular procedures in interventional radiology and neuroradiology. Queryo Medical sas distributes Glubran2 and radioprotection shields from WIT inc in France.
Website http://www.queryo-medical.com and www.gemitaly.it
Address 63, rue André Bollier 69307 LYON Cedex 07 - France
Contact FLORENCE CHAPPAT
Email [email protected]
Phone +33 6 88 61 38 34
MICROVENTION HOSPITALITY SUITE 07Presentation MicroVention is focused on proprietary technologies that provide therapeutic advantages for cerebral aneurysm treatment in a minimally invasive platform. The company currently markets and develops innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels and is committed to developing and manufacturing the highest quality products for its customers and patients.
Website http://www.microvention.com/
Address 1311 Valencia Avenue - CA 92780 TUSTIN - United States
Contact CATHY DEMYANOVICH
Email [email protected]
Phone (714) 247-8000, Ext. 8042
PENUMBRA BOOTH NUMBER 08Presentation Penumbra, Inc. is a privately held medical device company that strives to create and maintain a culture of innovation and independence to develop products that continuously challenge the status quo and improve patient outcomes. We deliver clinically beneficial devices to patients suffering from stroke and vascular disease. We are committed to the design, development and clinical application of innovative therapies in the neurovascular and peripheral vascular space.
Website http://www.penumbrainc.com
Address 1351 Harbor Bay Parkway - CA 94502 Alameda - United States
Contact ALAIN CORNIL
Email [email protected]
Phone +33679139172
14
Companies
STRYKERPresentation Stryker Neurovascular is committed to Complete Stroke Care through innovative products, technologies and services for ischemic and hemorrhagic stroke. By advancing the practice of less-invasive medecine, providing healthcare professionals more endovascular solutions and promoting clinical education and support, Stryker Neurovascular is dedicated to helping deliver better patient outcomes.
Website http://Stryker.com/neurovascular
Address 47900 Bayside Parkway - 94538-6515 FREMONT - United States
Contact SAMIA HADJ-MIMOUN
Email [email protected]